Catalyst Pharmaceuticals (CPRX) Retained Earnings (2010 - 2026)
Catalyst Pharmaceuticals posted quarterly Retained Earnings of $523.3 million for Q1 2026, up 3078623.53% year-on-year from N/an in Q1 2025, and up 10.37% on a QoQ basis from $474.2 million in Q4 2025.
Catalyst Pharmaceuticals (CPRX) has 17 years of Retained Earnings data on file, last reported at $523.3 million in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings rose 3078623.53% year-over-year to $523.3 million; the trailing twelve-month figure through Mar 2026 stood at $523.3 million (up 3078623.53% YoY), and the FY2025 full-year result was $474.2 million, up 740818.75% from the prior year.
- Retained Earnings for Q1 2026 stood at $523.3 million, up from $474.2 million in the prior quarter.
- Across five years, Retained Earnings topped out at $523.3 million in Q1 2026 and bottomed at -$453000.0 in Q1 2022.
- The 5-year median for Retained Earnings is $21500.0 (2022), against an average of $103.1 million.
- The widest annual swing landed in 2022, when Retained Earnings plunged 906.67%; it then soared 3078623.53% in 2026.
- A 5-year view of Retained Earnings shows it stood at $24000.0 in 2022, then plunged by 41.67% to $14000.0 in 2023, then jumped by 357.14% to $64000.0 in 2024, then soared by 740818.75% to $474.2 million in 2025, then gained by 10.37% to $523.3 million in 2026.
- The last three Retained Earnings figures came in at $523.3 million (Q1 2026), $474.2 million (Q4 2025), and $446.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -211.85 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | -153.89 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | -438.66 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -279.00 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 130.89 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 36.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | -24.89 Mn |
| 10 | Catalyst Pharmaceuticals | 3.82 Bn | 3.07 Bn | 134.92 Mn | 523.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 523.35 Mn |
| Dec 31, 2025 | 474.19 Mn |
| Sep 30, 2025 | 446.79 Mn |
| Jun 30, 2025 | 31,000.00 |
| Mar 31, 2025 | -17,000.00 |
| Dec 31, 2024 | 64,000.00 |
| Dec 31, 2023 | 14,000.00 |
| Sep 30, 2023 | 15,000.00 |
| Jun 30, 2023 | 19,000.00 |
| Mar 31, 2023 | 11,000.00 |
| Dec 31, 2022 | 24,000.00 |
| Sep 30, 2022 | 32,000.00 |
| Jun 30, 2022 | -130,000.00 |
| Mar 31, 2022 | -453,000.00 |
| Dec 31, 2021 | -148,000.00 |
| Sep 30, 2021 | -63,000.00 |
| Jun 30, 2021 | -37,000.00 |
| Mar 31, 2021 | -45,000.00 |
| Dec 31, 2020 | 31,000.00 |
| Sep 30, 2020 | -65.14 Mn |
| Jun 30, 2020 | -108.48 Mn |
| Mar 31, 2020 | 83,751.00 |
| Dec 31, 2019 | -128.69 Mn |
| Sep 30, 2019 | 19,428.00 |
| Jun 30, 2019 | -150.25 Mn |
| Mar 31, 2019 | -161.21 Mn |
| Dec 31, 2018 | -20,248.00 |
| Sep 30, 2018 | -146.06 Mn |
| Jun 30, 2018 | -36,498.00 |
| Mar 31, 2018 | -21,826.00 |
| Dec 31, 2017 | -126.56 Mn |
| Sep 30, 2017 | -121.17 Mn |
| Jun 30, 2017 | -117.00 Mn |
| Mar 31, 2017 | -113.12 Mn |
| Dec 31, 2016 | -108.15 Mn |
| Sep 30, 2016 | -103.98 Mn |
| Jun 30, 2016 | -100.03 Mn |
| Mar 31, 2016 | -95.46 Mn |
| Dec 31, 2015 | -90.08 Mn |
| Sep 30, 2015 | -84.26 Mn |
| Jun 30, 2015 | -79.81 Mn |
| Mar 31, 2015 | -75.25 Mn |
| Dec 31, 2014 | -69.84 Mn |
| Sep 30, 2014 | -66.35 Mn |
| Jun 30, 2014 | -61.34 Mn |
| Mar 31, 2014 | -58.14 Mn |
| Dec 31, 2013 | -54.33 Mn |
| Sep 30, 2013 | -52.98 Mn |
| Jun 30, 2013 | -47.07 Mn |
| Dec 31, 2012 | -42.18 Mn |
| Mar 31, 2012 | -39.19 Mn |
| Dec 31, 2011 | -38.10 Mn |
| Sep 30, 2011 | -35.75 Mn |
| Jun 30, 2011 | -34.62 Mn |
| Dec 31, 2010 | -31.71 Mn |